P21 – (42521-82-4)

P21 is a synthetic peptide derived from CNTF (Ciliary Neurotrophic Factor) that has shown promise in promoting neurogenesis and cognitive enhancement. Unlike CNTF, P21 is able to cross the blood-brain barrier due to its small size and the addition of an adamantane group, which increases its stability and permeability.

In animal studies, P21 has been demonstrated to boost levels of BDNF (Brain-Derived Neurotrophic Factor), a key protein involved in neuron growth and survival, thereby promoting neurogenesis in the dentate gyrus of the hippocampus. This region is crucial for the formation of new episodic memories and is one of the few areas in the adult brain where neurogenesis occurs.

P21’s ability to enhance neurogenesis has been linked to improved cognitive function, including better object discrimination and spatial reasoning in mouse models. Additionally, P21 has been shown to inhibit the formation of amyloid plaques and tau proteins, which are hallmarks of Alzheimer’s disease, by modulating the activity of GSK-3beta, a protein kinase implicated in the disease’s progression.

P21’s potential as a therapeutic agent is further supported by its ability to rescue cognitive deficits in rodent models of Alzheimer’s disease and Down syndrome. Despite its promising effects, P21 is currently only available for research purposes and has not yet been tested in human clinical trials.

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://en.wikipedia.org/wiki/P21
https://www.sciencedirect.com/science/article/pii/S001457931000520X
https://www.peptidesciences.com/p21-p021-5mg